Comments on: Globalization of Contract Research Organizations: Hope for Pharma Pipelines? http://bloggingbiotech.wordpress.com/2008/08/11/globalization-of-cros/ Just another WordPress.com weblog Fri, 12 Jun 2009 00:04:18 +0000 http://wordpress.com/ hourly 1 By: Jose http://bloggingbiotech.wordpress.com/2008/08/11/globalization-of-cros/#comment-362 Jose Wed, 10 Dec 2008 04:48:03 +0000 http://bloggingbiotech.wordpress.com/?p=158#comment-362 All this CRO business is eventually going to make a U turn to the US. With rising cost in India and China eventaully the difference is not going to be great. With the new government in place and tax benefits taken away from companies that outsource the incentive to outsource will decrease the pay gaps Jose All this CRO business is eventually going to make a U turn to the US. With rising cost in India and China eventaully the difference is not going to be great. With the new government in place and tax benefits taken away from companies that outsource the incentive to outsource will decrease the pay gaps

Jose

]]> By: CRO globalisation the “pipeline saviour”? « Clinical Research insights from CRfocus http://bloggingbiotech.wordpress.com/2008/08/11/globalization-of-cros/#comment-167 CRO globalisation the “pipeline saviour”? « Clinical Research insights from CRfocus Tue, 19 Aug 2008 14:15:42 +0000 http://bloggingbiotech.wordpress.com/?p=158#comment-167 [...] Andrew Smith on August 19, 2008 Over on the Blogging Biotech blog, Mary Canady has written about the globalisation of the CRO sector and how this could work for the benefit of pharma and biotech pi.... She makes some interesting points, but a more efficient clinical research sector also has some [...] [...] Andrew Smith on August 19, 2008 Over on the Blogging Biotech blog, Mary Canady has written about the globalisation of the CRO sector and how this could work for the benefit of pharma and biotech pi…. She makes some interesting points, but a more efficient clinical research sector also has some [...]

]]> By: Andrew Smith http://bloggingbiotech.wordpress.com/2008/08/11/globalization-of-cros/#comment-166 Andrew Smith Tue, 19 Aug 2008 14:08:09 +0000 http://bloggingbiotech.wordpress.com/?p=158#comment-166 Interesting piece... The importance of CROs having global reach while maintaining close links with pharma HQs has been great for the extablised players, who have gradually moved into Eastern Europe, India etc over the past 5-10 years. This hasn't been lost on the new generation of local CROs springing up in these regions, which had their initial growth from subcontracting from global CROs but are now emerging from their own countries and merging with other small/medium CROs from other countries (including developed countries) in an attempt to take on the big players at their own game of "global reach, local touch". The upshot of this will certainly be cost-containment for pharma, but the big question is how much of this will get reinvested into smarter drug discovery and earlier, more demanding go/no-go questions being asked of compounds, and more efficient scientific and operational models for how the clinical programme is conducted. The even bigger question is whether having a clinical research operation that is more efficient at weeding out compounds that don't meet the (more exacting) modern standards for safety and efficacy will improve or actually damage the size of the pipeline. You've got to have good compounds going into testing to be able to withstand the attrition that a good clinical research operating is always going to deliver... Interesting piece…

The importance of CROs having global reach while maintaining close links with pharma HQs has been great for the extablised players, who have gradually moved into Eastern Europe, India etc over the past 5-10 years. This hasn’t been lost on the new generation of local CROs springing up in these regions, which had their initial growth from subcontracting from global CROs but are now emerging from their own countries and merging with other small/medium CROs from other countries (including developed countries) in an attempt to take on the big players at their own game of “global reach, local touch”.

The upshot of this will certainly be cost-containment for pharma, but the big question is how much of this will get reinvested into smarter drug discovery and earlier, more demanding go/no-go questions being asked of compounds, and more efficient scientific and operational models for how the clinical programme is conducted.

The even bigger question is whether having a clinical research operation that is more efficient at weeding out compounds that don’t meet the (more exacting) modern standards for safety and efficacy will improve or actually damage the size of the pipeline. You’ve got to have good compounds going into testing to be able to withstand the attrition that a good clinical research operating is always going to deliver…

]]> By: Jamie Laycock http://bloggingbiotech.wordpress.com/2008/08/11/globalization-of-cros/#comment-165 Jamie Laycock Mon, 18 Aug 2008 13:23:39 +0000 http://bloggingbiotech.wordpress.com/?p=158#comment-165 We are a full- service clinical research organization in India with experience in all phases of clinical trials and in all key areas of the drug development process. And I am fully agree with you. We have cost advantage over many developed countries and also for our trials we get human resource very fairly. Thanks for mentioning India's name in your blog post We are a full- service clinical research organization in India with experience in all phases of clinical trials and in all key areas of the drug development process. And I am fully agree with you. We have cost advantage over many developed countries and also for our trials we get human resource very fairly. Thanks for mentioning India’s name in your blog post

]]>